MIRABEGRON AND UAS OUTCOMES DURING RIRS

The aim of this study is to evaluate whether there is a difference in the passage rate of the ureteral access sheath between patients who used mirabegron (a beta-3 receptor agonist) for overactive bladder and those who underwent retrograde intrarenal surgery for kidney stones, and those who did not use mirabegron. Considering that beta-3 receptors in the smooth muscle of the ureter cause relaxation in the ureter, the hypothesis that the passage rate of the access sheath increases in those using mirabegron, thus facilitating access to kidney stones and improving surgical success, will be investigated.

NCT Number	NCT07566416
Lead Sponsor	Ankara Training and Research Hospital
Conditions	Kidney Stone, Retrograde Intrarenal Surgery (RIRS), Ureteral Access Sheath
Enrollment	131 participants
Start Date	2018-01-01
Primary Completion	2021-10-30 (estimated)
Study Completion	2025-02-10 (estimated)
Updated on ClinicalTrials.gov	2026-05-14